PE20071021A1 - Composicion farmaceutica que comprende un compuesto de amonio cuaternario y una fluoroquinolona - Google Patents

Composicion farmaceutica que comprende un compuesto de amonio cuaternario y una fluoroquinolona

Info

Publication number
PE20071021A1
PE20071021A1 PE2007000249A PE2007000249A PE20071021A1 PE 20071021 A1 PE20071021 A1 PE 20071021A1 PE 2007000249 A PE2007000249 A PE 2007000249A PE 2007000249 A PE2007000249 A PE 2007000249A PE 20071021 A1 PE20071021 A1 PE 20071021A1
Authority
PE
Peru
Prior art keywords
fluoroquinolone
quaternary ammonium
ammonium compound
pharmaceutical composition
chloride
Prior art date
Application number
PE2007000249A
Other languages
English (en)
Inventor
Iris Heep
Kristine Fraatz
Hans-Jurgen Hamann
Markus Edingloh
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38171208&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20071021(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of PE20071021A1 publication Critical patent/PE20071021A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN COMPUESTO DE AMONIO CUATERNARIO DE FORMULA (III) DONDE R1, R2, R3 Y R4 SON CADA UNO ALQUILO(C1-C18) OPCIONALMENTE INTERRUMPIDO POR O, O FORMAN UN HETEROCICLO DE 5 A 6 MIEMBROS TAL COMO PIRIDINA O TIAZOLINA, ENTRE OTROS; X ES SULFATO, HALOGENURO, ENTRE OTROS; SIENDO PREFERIDOS: CLORUROS DE ALQUILDIMETILBENCILAMONIO, CLORURO DE BENZALCONIO, CLORURO DE BENCETONIO, BROMURO DE N-HEXADECIL-N,N-TRIMETILAMONIO, CLORURO DE 1-HEXADECILPIRIDINIO, ENTRE OTROS; B) UNA FLUOROQUINOLONA TAL COMO CIPROFLOXACINO, ENROFLOXACINO, PRADOFLOXACINO O MARBOFLOXACINO; Y C) UN CATION METALICO DI- O TRIVALENTE TAL COMO Mg2+. DICHO COMPUESTO DE AMONIO CUATERNARIO EVITA LA PRECIPITACION DE LA FLUOROQUINOLONA EN DISOLUCION SIENDO ADECUADOS PARA APLICACION PARENTERAL
PE2007000249A 2006-03-08 2007-03-07 Composicion farmaceutica que comprende un compuesto de amonio cuaternario y una fluoroquinolona PE20071021A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006010643A DE102006010643A1 (de) 2006-03-08 2006-03-08 Arzneimittel enthaltend Fluorchinolone

Publications (1)

Publication Number Publication Date
PE20071021A1 true PE20071021A1 (es) 2007-11-25

Family

ID=38171208

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000249A PE20071021A1 (es) 2006-03-08 2007-03-07 Composicion farmaceutica que comprende un compuesto de amonio cuaternario y una fluoroquinolona

Country Status (31)

Country Link
US (1) US10231925B2 (es)
EP (2) EP1993510A1 (es)
JP (1) JP5584418B2 (es)
KR (2) KR20150046367A (es)
CN (2) CN101394836B (es)
AR (1) AR059696A1 (es)
AU (1) AU2007291622B2 (es)
BR (1) BRPI0708613B1 (es)
CA (1) CA2645037C (es)
CR (1) CR10270A (es)
DE (1) DE102006010643A1 (es)
DK (1) DK2340809T3 (es)
EC (1) ECSP088716A (es)
ES (1) ES2542206T3 (es)
GT (1) GT200800173A (es)
HU (1) HUE025044T2 (es)
IL (1) IL193429A0 (es)
MX (1) MX2008011344A (es)
MY (1) MY152885A (es)
NZ (1) NZ571046A (es)
PE (1) PE20071021A1 (es)
PL (1) PL2340809T3 (es)
PT (1) PT2340809E (es)
RU (1) RU2527327C2 (es)
SI (1) SI2340809T1 (es)
SV (1) SV2008003014A (es)
TW (1) TWI494105B (es)
UA (1) UA96753C2 (es)
UY (1) UY30191A1 (es)
WO (1) WO2008025380A1 (es)
ZA (1) ZA200807484B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1405890B2 (en) 2001-05-15 2017-03-15 Eurokera Thermochromic material
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
WO2010069493A1 (de) * 2008-12-18 2010-06-24 Bayer Animal Health Gmbh Verbesserte wirkstoffkombination enthaltend ein antibiotikum und einen nichtsteroidalen entzündungshemmer (nsaid)
EP2332916A3 (en) 2009-11-19 2011-08-03 Krka Tovarna Zdravil, D.D., Novo Mesto A process for a preparation of marbofloxacin and intermediate thereof
CN101716141B (zh) * 2010-01-20 2011-11-30 白求恩医科大学制药厂 一种氟罗沙星注射液及其制备方法
GB2480276A (en) * 2010-05-11 2011-11-16 Michael Hilary Burke Process for the preparation of an aqueous injectable enrofloxacin antimicrobial formulation
RU2682171C2 (ru) * 2016-10-11 2019-03-15 Закрытое Акционерное Общество "Биологические Исследования И Системы" (Зао "Бис") Фармацевтическая комбинированная композиция для лечения гнойных ран на основе фторхинолонов (варианты)
WO2018083675A1 (en) * 2016-11-07 2018-05-11 Jubilant Life Sciences Limited Synergistic antimicrobial compositions
CA3053211A1 (en) * 2017-02-13 2018-08-16 Bayer Animal Health Gmbh Liquid composition containing pradofloxacin and antioxidants
WO2019023842A1 (en) 2017-07-31 2019-02-07 Dow Silicones Corporation MOISTURE CURING COMPOSITIONS
KR20200037276A (ko) 2017-07-31 2020-04-08 다우 실리콘즈 코포레이션 수분 경화성 조성물
CN111620901B (zh) * 2020-06-08 2023-03-21 蚌埠医学院第二附属医院 一种含硅氧烷基的氟喹诺酮化合物、其制备方法及用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4670444B1 (en) 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4472405A (en) 1982-11-12 1984-09-18 Riker Laboratories, Inc. Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives
US4730000A (en) 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
US4551456A (en) * 1983-11-14 1985-11-05 Merck & Co., Inc. Ophthalmic use of norfloxacin and related antibiotics
AT392789B (de) 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
IN166416B (es) 1985-09-18 1990-05-05 Pfizer
DE3713672A1 (de) 1987-04-24 1988-11-17 Bayer Ag Verfahren zur herstellung von parenteral verabreichbaren chinoloncarbonsaeuren
DE3831514A1 (de) 1988-09-16 1990-03-22 Bayer Ag Ph-neutrale waessrige loesungen von chinoloncarbonsaeuren
US5225413A (en) 1988-09-16 1993-07-06 Bayer-Aktiengesellschaft pH-neutral aqueous solutions of quinolone-carboxylic acids
JP2832535B2 (ja) 1989-04-04 1998-12-09 富山化学工業株式会社 キノロンカルボン酸またはその塩の可溶化法
WO1991009616A1 (en) 1989-12-22 1991-07-11 Yale University Quinolone antibiotics encapsulated in lipid vesicles
ES2102393T3 (es) 1989-12-29 1997-08-01 Abbott Lab Complejos de acido quinolona carboxilico--ion metalico--acido.
FR2665635A1 (fr) * 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
DE69224071T2 (de) 1991-09-17 1998-05-07 Alcon Lab Inc Chinolan-antibiotika und polystyrolsulfonat enthaltende zusammensetzungen
NZ501160A (en) 1995-12-21 2001-10-26 Pfizer Subcutaneously injectable quinolone formulations with zinc or magnesium compounds and a co-solvent
US6323213B1 (en) 1996-02-23 2001-11-27 Bayer Aktiengesellschaft Possibly substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives
WO1998018492A1 (fr) 1996-10-25 1998-05-07 Yoshitomi Pharmaceutical Industries Ltd. Procede pour empecher la precipitation de medicaments
GB9714218D0 (en) 1997-07-04 1997-09-10 Allied Therapeutics Ltd Peritoneal dialysis fluid
DE19729879C2 (de) * 1997-07-11 1999-07-08 Mann Gerhard Chem Pharm Fab Lagerstabile ophthalmische Zusammensetzungen, umfassend Diclofenac und Ofloxacin
US6387928B1 (en) 1997-09-15 2002-05-14 The Procter & Gamble Co. Antimicrobial quinolones, their compositions and uses
SK286420B6 (sk) * 1997-09-15 2008-09-05 The Procter & Gamble Company Zlúčenina so štruktúrou chinolónu, farmaceutický prostriedok s jej obsahom a jej použitie
US6605751B1 (en) 1997-11-14 2003-08-12 Acrymed Silver-containing compositions, devices and methods for making
ID21415A (id) 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
DE19918324A1 (de) * 1999-04-22 2000-10-26 Mann Gerhard Chem Pharm Fab Pharmazeutische Zusammensetzung wirksam gegen durch Bakterien, Viren, Pilze, Hefen und Protozoen verursachte Krankheitszustände
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
PL201130B1 (pl) 1999-09-24 2009-03-31 Alcon Inc Kompozycje zawiesinowe zawierające ciprofloksacynę i deksametazon do podawania miejscowego do oczu, uszu lub nosa
WO2004087043A2 (en) * 2003-02-21 2004-10-14 Sun Pharmaceutical Industries Limited Stable ophthalmic formulation containing an antibiotic and a corticosteroid
DE10312346A1 (de) 2003-03-20 2004-09-30 Bayer Healthcare Ag Kontrolliertes Freisetzungssystem
RU2248199C1 (ru) * 2003-06-02 2005-03-20 Открытое Акционерное Общество "Акционерное Курганское общество медицинских препаратов и изделий "Синтез" (ОАО "Синтез") Глазные капли и способ их получения
DE10337191A1 (de) * 2003-08-13 2005-03-17 Bayer Healthcare Ag Neue Verwendung von Chinolon-Antibiotika
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
DE102004015981A1 (de) 2004-04-01 2005-10-20 Bayer Healthcare Ag Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
CN102499928A (zh) * 2004-08-13 2012-06-20 先灵-普劳有限公司 包含抗菌素、三唑和皮质类固醇的药物制剂

Also Published As

Publication number Publication date
US10231925B2 (en) 2019-03-19
JP5584418B2 (ja) 2014-09-03
EP2340809A2 (de) 2011-07-06
DK2340809T3 (en) 2015-07-20
AU2007291622A1 (en) 2008-03-06
EP2340809A3 (de) 2012-09-19
ES2542206T3 (es) 2015-08-03
CN101394836B (zh) 2017-08-29
BRPI0708613B1 (pt) 2021-10-19
JP2009529015A (ja) 2009-08-13
SV2008003014A (es) 2010-05-17
KR20080106253A (ko) 2008-12-04
CR10270A (es) 2009-03-18
ECSP088716A (es) 2008-11-27
CA2645037A1 (en) 2008-03-06
RU2527327C2 (ru) 2014-08-27
TW200810756A (en) 2008-03-01
WO2008025380A1 (de) 2008-03-06
GT200800173A (es) 2009-09-14
NZ571046A (en) 2012-05-25
CA2645037C (en) 2016-06-28
EP1993510A1 (de) 2008-11-26
RU2008139635A (ru) 2010-04-20
ZA200807484B (en) 2009-11-25
SI2340809T1 (sl) 2015-08-31
PT2340809E (pt) 2015-08-28
DE102006010643A1 (de) 2007-09-13
BRPI0708613A2 (pt) 2011-06-07
IL193429A0 (en) 2009-05-04
EP2340809B1 (de) 2015-04-15
PL2340809T3 (pl) 2015-09-30
AU2007291622B2 (en) 2013-08-01
CN104208064A (zh) 2014-12-17
KR20150046367A (ko) 2015-04-29
UA96753C2 (ru) 2011-12-12
CN101394836A (zh) 2009-03-25
MY152885A (en) 2014-11-28
UY30191A1 (es) 2007-10-31
US20100009979A1 (en) 2010-01-14
TWI494105B (zh) 2015-08-01
MX2008011344A (es) 2008-11-12
HUE025044T2 (en) 2016-01-28
AR059696A1 (es) 2008-04-23

Similar Documents

Publication Publication Date Title
PE20071021A1 (es) Composicion farmaceutica que comprende un compuesto de amonio cuaternario y una fluoroquinolona
BR112014018702A8 (pt) Composto, cristal, inibidor, medicamento, composição farmacêutica, e, uso de um composto ou sal
CY1120269T1 (el) Ετεροδικυκλικες ενωσεις ως αναστολεις βητα-λακταμασης
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
AR055563A1 (es) Compuestos de piridil acido acetico, agente farmaceutico y utilizacion del compuesto para preparar dicho agente
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
PH12016500756A1 (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
PH12016502582B1 (en) TrK-INHIBITING COMPOUND
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
PE20130306A1 (es) Morfolinopirimidinas y su uso en terapia
AR059338A1 (es) N-fenilbenzotriazolilo como inhibidores de c-kit
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
BR112013004231A2 (pt) derivados de heteroariliperidina e piperazina como fungicidas
PE20161246A1 (es) Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
TN2013000275A1 (en) Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
MX2009005264A (es) Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos.
MY156270A (en) Substituted aminopropionic derivatives as neprilysin inhibitors
NZ607794A (en) N-acylsulfonamide apoptosis promoters
RS53342B (en) DERIVATIVES OF PRIVATE AND INHIBITORIES MEK
PE20120049A1 (es) Derivados de 3-anilino-tieno[3, 2-c]piridina como inhibidores de quinasa mek
PE20090679A1 (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
PE20141691A1 (es) Compuestos con actividad nematicida
CO6321166A2 (es) Compuestos de pirrol
PE20141828A1 (es) 6-alquinilo piridinas como mimeticos smac

Legal Events

Date Code Title Description
FC Refusal